Business
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
CULVER CITY, Calif., April 21, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom:
About this update from Immunitybio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/c1cf040718d5c0fdf0f8632c45c82b83"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dM3.gPljr2THwazCIpUQmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/c1cf040718d5c0fdf0f8632c45c82b83","width":480,"height":270}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"ANKTIVA approved for patients with certain indications of non-muscle invasive bladder cancer and non-small cell lung cancer","length":123,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Commercial availability achieved within two months of announcing MENA partnership with Biopharma and Cigalah Healthcare","length":119,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"First patients to be dosed have been identified and will soon receive initial ANKTIVA treatment","length":95,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":337,"olType":false},{"type":"text","content":"CULVER CITY, Calif., April 21, 2026--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that ANKTIVA® (nogapendekin alfa inbakicept) is now commercially available in Saudi Arabia. Initial patients have been identified for treatment across both approved bladder and lung cancer indications in the Kingdom:","length":362,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"In combination with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease; and","length":215,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"In combination with an immune checkpoint inhibitor for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC), as authorized by the Saudi Food and Drug Authority (SFDA)","length":196,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":411,"olType":false},{"type":"text","content":"ANKTIVA is being distributed through ImmunityBio’s partnerships with Biopharma and Cigalah Healthcare, leading healthcare distribution...